Institut Pasteur spinout Invectys will use the funding to advance a drug candidate for a type of leukaemia into a phase 2 trial.

The Legend Capital-backed sacral neuromodulation device developer floated in the middle of its range while upping the number of shares in the IPO.

Novartis and Access Industries were among the investors that bought $37.5m of the shares, which the cell therapy developer issued at a downgraded price.

The firm, formed by Astellas and MPM Capital two years ago, has secured $75m for a fund known as Rx Digital Fund, according to a securities filing.

The smoking cessation system developer has secured $25m in a round led by Johnson & Johnson Innovation – JJDC that included New York Life Ventures.

Nova University Lisbon has established chemicals producer Des Solutio with the support of Frontier IP, making it the second spinout launched in Portugal by the commercialisation firm.

Novo has returned for Milestone's latest round, having led its $55m series C last year, helping the cardiovascular drug developer's total funding to $167m.

Bristol Myers-Squibb, Merck Group and Novo all took part in a $90m series C round for Galecto Biotech, which is commercialising research from Lund and Edinburgh universities.

Quark Venture and GF Securities have invested $1.9m in Sitka Biopharma, a spinout of University of British Columbia and Centre for Drug Research and Development.

Bristol Myers-Squibb, Merck Group and Novo all took part in a $90m series C round for Galecto Biotech that was co-led by Ysios Capital and OrbiMed.